Polatuzumab Vedotin Clinical Trials

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

Total Trials

Recruiting

Completed

11,179

Total Enrollment

States

Polatuzumab Vedotin Evidence & Publications

33 peer-reviewed publications + per-arm primary-outcome data from 6 pivotal trials.

See published evidence →

Polatuzumab Vedotin Clinical Trials

Sortable list of all 80 Polatuzumab Vedotin trials — recruiting status, pivotal acronyms, indication grouping, NCT links.

See all trials →

What Is Polatuzumab Vedotin?

Polatuzumab Vedotin is a type of medication that combines a monoclonal antibody with a chemotherapy drug. This drug specifically targets CD19, a protein found on the surface of certain cancer cells, particularly B-cells. By attaching to CD19, Polatuzumab Vedotin delivers the chemotherapy directly to these cancerous cells, helping to destroy them while minimizing harm to healthy cells.

This drug is currently being investigated in clinical trials for various types of lymphoma. Studies are evaluating its efficacy and safety in conditions such as Richter's Transformation that has evolved from chronic lymphocytic leukemia, previously untreated high-risk Diffuse Large B-cell Lymphoma (DLBCL), and DLBCL that has either returned or not improved after previous treatments (relapsed or refractory DLBCL).

Uses and Conditions Under Study

Polatuzumab Vedotin is being studied for its potential to treat several types of lymphoma, which are cancers that begin in the lymphatic system. The drug's mechanism of targeting CD19-expressing B-cells makes it relevant for lymphomas originating from these cells.

Diffuse Large B-cell Lymphoma (DLBCL): This is the most frequently studied condition, with approximately 34 trials investigating Polatuzumab Vedotin for various forms of DLBCL, including previously untreated, high-risk, relapsed, and refractory cases. DLBCL is a fast-growing type of non-Hodgkin lymphoma, and Polatuzumab Vedotin aims to deliver targeted chemotherapy to the cancerous B-cells.
Other Non-Hodgkin Lymphomas: Broader categories such as Lymphoma, Non-Hodgkin Lymphoma, and B-Cell Lymphoma are being studied in about 14 trials. These trials explore the drug's effectiveness across a wider spectrum of B-cell lymphomas, where the CD19 target is also present.
Follicular Lymphoma: This slower-growing type of non-Hodgkin lymphoma is also under investigation, with 3 trials exploring the use of Polatuzumab Vedotin.
High-grade B-cell Lymphoma and Richter's Transformation: These aggressive forms of B-cell lymphoma are also subjects of clinical research for Polatuzumab Vedotin, as highlighted in trial summaries.

Dosing

Polatuzumab Vedotin is administered as an intravenous infusion. The specific dosage and schedule can vary depending on the clinical trial and the combination therapy being used.

Commonly studied dosages include 1.8 mg/kg, which is often given on Day 1 of each 21-day cycle, or on Day 2 of Cycle 1 and Day 1 of subsequent cycles. Other strengths that have been investigated in various treatment regimens include 1.0 mg/kg, 1.4 mg/kg, and 2.4 mg/kg. The total number of treatment cycles can vary, with some regimens specifying up to 6 cycles or 12 cycles.

These dosages are typically for adult patients, and the drug is often administered as part of a multi-drug regimen, such as Pola-R-CHP or Pola-ZR-Glo, rather than as a standalone treatment. Information regarding specific pediatric dosing is not detailed in the provided trial data.

Side Effects

In a clinical trial involving patients with B-cell non-Hodgkin's lymphoma, side effects were observed in patients taking Polatuzumab Vedotin compared to those receiving a placebo. This trial included 27 patients in the Polatuzumab Vedotin arm and 14 patients in the placebo arm.

The most common side effects experienced by patients taking Polatuzumab Vedotin included:

Decreased white blood cell count: 74.1% of patients taking Polatuzumab Vedotin experienced this, compared to 64.3% on placebo.
Decreased neutrophil count: 70.4% of patients on Polatuzumab Vedotin, compared to 50.0% on placebo.
Anemia (low red blood cell count): 59.3% of patients on Polatuzumab Vedotin, compared to 35.7% on placebo.
Decreased platelet count: 55.6% of patients on Polatuzumab Vedotin, compared to 50.0% on placebo.
Hypokalemia (low potassium levels): 44.4% of patients on Polatuzumab Vedotin, compared to 28.6% on placebo.
Nausea: 40.7% of patients on Polatuzumab Vedotin, compared to 28.6% on placebo.
Pyrexia (fever): 37.0% of patients on Polatuzumab Vedotin, compared to 7.1% on placebo.
Vomiting: 37.0% of patients on Polatuzumab Vedotin, compared to 28.6% on placebo.
Diarrhea: 25.9% of patients on Polatuzumab Vedotin, compared to 0.0% on placebo.

Clinical Trial Results

Clinical trials have evaluated Polatuzumab Vedotin for the treatment of various types of B-cell non-Hodgkin's lymphoma (NHL), including Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL).

Study NCT01691898: Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

This study investigated Polatuzumab Vedotin in combination with Rituximab (RTX) or Obinutuzumab for patients with relapsed or refractory NHL. Key efficacy results include:

Duration of Objective Response (DOR): In DLBCL, patients treated with RTX + Polatuzumab Vedotin (Arm B) had a median DOR of 13.37 months. For FL, patients receiving RTX + Polatuzumab Vedotin (Cohort C) had a median DOR of 12.85 months.
Overall Survival (OS): In DLBCL, patients receiving RTX + Polatuzumab Vedotin (Arm B) had a median OS of 18.760 months. For DLBCL patients treated with Obinutuzumab + Polatuzumab Vedotin, the median OS was 10.5 months.
Progression-Free Survival (PFS): In FL, patients receiving RTX + Polatuzumab Vedotin (Cohort C) had a median PFS of 18.103 months. For FL patients treated with Obinutuzumab + Polatuzumab Vedotin, the median PFS was 19.5 months.
Overall Response Rate (ORR): In FL, 75.0% of patients treated with RTX + Polatuzumab Vedotin (Cohort C) achieved a complete or partial response.

Study NCT01992653: B-Cell Non-Hodgkin's Lymphoma

This study explored Polatuzumab Vedotin in combination with Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP or G-CHP). Notable results include:

Objective Response Rate: In the DLBCL population, 76.5% of patients receiving Polatuzumab Vedotin (1.8mg) + G-CHP achieved an objective response (complete or partial response). In the Non-DLBCL population, 100.0% of patients receiving Polatuzumab Vedotin (1.8mg) + R-CHP achieved an objective response.
Overall Survival (OS): For the Non-DLBCL population, the median OS was 15.24 months for patients treated with Polatuzumab Vedotin (1.8mg) + R-CHP.
Peripheral Neuropathy: Patients reported generally low mean scores for numbness/tingling (ranging from 0 to 2 on a questionnaire scale) and overall neuropathy severity (ranging from 0 to 1.56), suggesting mild to moderate symptoms.

Study NCT02257567: Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

This trial compared Polatuzumab Vedotin (Pola) combined with Bendamustine (B) and Rituximab (R) (Pola+BR) against BR alone for DLBCL. It also studied Pola+BR and Pola+BG (Obinutuzumab) for FL.

Best Objective Response (BOR) in DLBCL: 62.5% of patients on Pola+BR achieved a best objective response, compared to 25.0% on BR alone.
Progression-Free Survival (PFS) in DLBCL: The median PFS for patients on Pola+BR was 9.248 months, significantly longer than 3.713 months for those on BR alone.
Complete Response (CR) in FL: For FL, 69.2% of patients on Pola+BR achieved a complete response based on PET-CT scans, compared to 63.4% on BR alone.

Study NCT02600897: Relapsed or Refractory Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)

This study combined Polatuzumab Vedotin (Pola) with Lenalidomide (L) and either Obinutuzumab (G) for FL or Rituximab (R) for DLBCL. In the expansion phase:

Objective Response (OR) at End of Induction (EOI): 72.50% of FL patients on Pola (1.4mg) + L (20mg) + G achieved an objective response. For DLBCL patients on Pola (1.8mg) + L (20mg) + R, 46.20% achieved an objective response.
Complete Response (CR) at EOI: 60.0% of FL patients on Pola (1.4mg) + L (20mg) + G achieved a complete response. For DLBCL patients on Pola (1.8mg) + L (20mg) + R, 38.5% achieved a complete response.

Study NCT02611323: Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

This study investigated Polatuzumab Vedotin (Pola) in combination with Venetoclax (V) and Rituximab (R) or Obinutuzumab (G). In the dose expansion phase:

Objective Response (OR) at EOI: 70.7% of FL patients on Pola (1.8mg) + V (800mg) + G achieved an objective response. For DLBCL patients on Pola (1.8mg) + V (800mg) + R, 37.5% achieved an objective response.
Complete Response (CR) at EOI: 51.2% of FL patients on Pola (1.8mg) + V (800mg) + G achieved a complete response. For DLBCL patients on Pola (1.8mg) + V (800mg) + R, 32.5% achieved a complete response.

Currently Recruiting Trials

Clinical researchers are actively investigating Polatuzumab Vedotin, often in combination with other therapies, for various types of lymphoma. These studies aim to understand its effectiveness and safety in different patient populations and disease stages. If you or a loved one are considering participating in a clinical trial, here are some of the studies currently recruiting patients:

A Phase 2 study, NCT07514169, sponsored by Ruijin Hospital, is evaluating the Pola-ZR-Glo regimen (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide, and Glofitamab) in older patients with previously untreated Large B-Cell Lymphoma (LBCL). This single-arm study is recruiting 30 participants.
Another Phase 2 study, NCT07001540, from Fudan University, is assessing Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as a salvage therapy. This trial is for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) who are not eligible for autologous transplantation and aims to enroll 130 individuals.
Merck Sharp & Dohme LLC is sponsoring a large Phase 2 study, NCT06890884, comparing Zilovertamab Vedotin plus R-CHP against Polatuzumab Vedotin plus R-CHP in people with Diffuse Large B-cell Lymphoma (DLBCL). This study is designed to enroll 594 participants.
For patients with Secondary Central Nervous System (CNS) Lymphoma, a Phase 1 study, NCT06730542, led by Juan P. Alderuccio, MD, is investigating Zanubrutinib in combination with Pola-R-CHP and high-dose Methotrexate. This trial is recruiting 20 patients to determine the effects of this combination.
Ruijin Hospital is also conducting a Phase 3 randomized trial, NCT06522555, to compare the efficacy and safety of Pola-ZR2 (Polatuzumab Vedotin, Zanubrutinib, Rituximab, and Lenalidomide) versus ZR2 (Zanubrutinib, Rituximab, and Lenalidomide) in older patients with newly diagnosed Diffuse Large B-cell Lymphoma. This study plans to enroll 100 participants.
A Phase 2 study, NCT06043674, sponsored by Christine Ryan, is exploring Glofitamab as monotherapy or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab for Richter's Transformation, a rare form of Chronic Lymphocytic Leukemia. This study is recruiting 70 patients.
The SWOG Cancer Research Network is conducting a Phase 2 trial, NCT05633615, testing drug treatments after CAR T-cell therapy in patients with relapsed or refractory Diffuse Large B-cell Lymphoma. This study evaluates mosunetuzumab and/or Polatuzumab Vedotin and aims to enroll 396 participants.
ADC Therapeutics S.A. is sponsoring a Phase 1 study, NCT04970901, to evaluate the safety and anti-cancer activity of Loncastuximab Tesirine in combination with other agents, including Polatuzumab Vedotin, in participants with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This trial is recruiting 200 patients.

Where to Participate

Clinical trials for Polatuzumab Vedotin are being conducted across a wide geographic area, offering opportunities for participation in many locations. There are currently 245 study sites in 158 cities across 43 states. The top cities with the most recruiting sites include:

New York, New York (9 sites)
Boston, Massachusetts (7 sites)
Portland, Oregon (6 sites)
Atlanta, Georgia (6 sites)
Cleveland, Ohio (6 sites)
Philadelphia, Pennsylvania (5 sites)
Miami, Florida (5 sites)
Charlotte, North Carolina (4 sites)
Winston-Salem, North Carolina (4 sites)
Chicago, Illinois (4 sites)

Eligibility criteria for these trials generally include individuals aged 12 to 100 years, of all genders. Healthy volunteers are typically not sought for these studies, which focus on patients with specific medical conditions.

Development Timeline

The journey of Polatuzumab Vedotin in clinical development began on February 7, 2011, with the latest trials extending into May 2026. Over this period, a total of 80 clinical trials have been initiated, enrolling more than 11,179 participants. Early development saw Polatuzumab Vedotin primarily investigated for various lymphomas, including Lymphoma, Non-Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma. As research progressed, the scope expanded to include more specific types such as High-grade B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, and conditions like Richter's Transformation. The majority of these studies have been conducted in Phase 2, with 44 trials, followed by 17 trials in Phase 1/Phase 2, 10 in Phase 1, and 7 in Phase 3. Hoffmann-La Roche has been a significant driver in this development, sponsoring 16 trials. Other notable sponsors include Ruijin Hospital with 6 trials, and the University of Washington and Genentech, Inc., each sponsoring 3 trials. This extensive research reflects a continuous effort to understand and optimize Polatuzumab Vedotin's potential in treating a broad spectrum of B-cell lymphomas.

Polatuzumab Vedotin Development Timeline

Clinical trial activity from 2011 to 2026.

2026

NCT06594939PHASE2not yet recruiting

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

31 enrolled

NCT07594899PHASE2not yet recruiting

AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL

178 enrolled

NCT07502872PHASE2not yet recruiting

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

30 enrolled

NCT07415980PHASE1/PHASE2not yet recruiting

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

68 enrolled

NCT07514169PHASE2recruiting

The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL

30 enrolled

NCT07397832PHASE2recruiting

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

58 enrolled

NCT07231250PHASE2not yet recruiting

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

40 enrolled

2025

NCT07184788PHASE2not yet recruiting

G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma

80 enrolled

NCT06665217PHASE2not yet recruiting

G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

80 enrolled

NCT07122609PHASE2not yet recruiting

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

22 enrolled

NCT07034508PHASE2not yet recruiting

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

134 enrolled

NCT07012980PHASE2not yet recruiting

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

38 enrolled

NCT07001540PHASE2recruiting

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

130 enrolled

NCT06730542PHASE1recruiting

Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma

20 enrolled

NCT06890884PHASE2recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

594 enrolled

NCT06803693PHASE2recruiting

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

152 enrolled

NCT06765317PHASE2recruiting

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

42 enrolled

2024

NCT06441097PHASE2not yet recruiting

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

152 enrolled

NCT06516978PHASE2not yet recruiting

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

528 enrolled

NCT06664411PHASE2recruiting

Pola-ZR2P in Previously Untreated DLBCL

80 enrolled

NCT06453044PHASE2recruiting

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

41 enrolled

NCT06554600PHASE2recruiting

A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

36 enrolled

NCT06071871PHASE2recruiting

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

99 enrolled

NCT06530511PHASE2recruiting

Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

30 enrolled

NCT06522555PHASE3recruiting

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

100 enrolled

NCT06015880PHASE1recruiting

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

30 enrolled

NCT06043674PHASE2recruiting

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

70 enrolled

NCT05868395PHASE2recruiting

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

16 enrolled

2023

NCT06176729PHASE2recruiting

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

30 enrolled

NCT06040320PHASE1/PHASE2recruiting

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

12 enrolled

NCT06047080PHASE3active not recruiting

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

1,130 enrolled

NCT05954910active not recruiting

A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

1,000 enrolled

NCT05940051PHASE2unknown

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

35 enrolled

NCT05940064PHASE2unknown

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

30 enrolled

NCT06468943PHASE2enrolling by invitation

Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

20 enrolled

NCT05633615PHASE2recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

396 enrolled

NCT05615636PHASE2recruiting

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

36 enrolled

NCT05800366PHASE2recruiting

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

41 enrolled

NCT05798156PHASE2active not recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

125 enrolled

NCT05498220PHASE2terminated

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

5 enrolled

NCT05455697PHASE1/PHASE2recruiting

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

35 enrolled

2022

NCT05260957PHASE2recruiting

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

22 enrolled

NCT05410418PHASE2active not recruiting

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

34 enrolled

NCT04970901PHASE1recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

200 enrolled

NCT05283720PHASE2recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

NCT05171647PHASE3active not recruiting

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

208 enrolled

NCT05169658PHASE2completed

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

42 enrolled

2021

NCT04882163PHASE1/PHASE2withdrawn

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

0 enrolled

NCT04679012PHASE2recruiting

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

20 enrolled

NCT04594798PHASE2active not recruiting

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

39 enrolled

NCT04884035PHASE1recruiting

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

224 enrolled

NCT04913103PHASE2not yet recruiting

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

21 enrolled

NCT04491370PHASE1/PHASE2recruiting

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

20 enrolled

NCT04739813PHASE1active not recruiting

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

34 enrolled

NCT04790903PHASE1terminated

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

50 enrolled

NCT04914741PHASE1/PHASE2active not recruiting

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

80 enrolled

NCT04833114PHASE3completed

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

306 enrolled

NCT04659044PHASE2terminated

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

3 enrolled

NCT04535102PHASE2withdrawn

POLA+BR for Relapsed or Refractory DLBCL

0 enrolled

NCT04665765PHASE2active not recruiting

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

41 enrolled

2020

NCT04607772PHASE1/PHASE2withdrawn

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

0 enrolled

NCT04231877PHASE1recruiting

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

56 enrolled

NCT04479267PHASE2active not recruiting

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

8 enrolled

NCT04236141PHASE3terminated

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

42 enrolled

NCT04323956PHASE1active not recruiting

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

50 enrolled

NCT04182204PHASE3completed

A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

270 enrolled

2019

NCT04624893unknown

A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin

35 enrolled

NCT03677154PHASE1/PHASE2completed

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

188 enrolled

NCT03677141PHASE1/PHASE2completed

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

117 enrolled

2018

NCT03671018PHASE1/PHASE2active not recruiting

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

422 enrolled

NCT03533283PHASE1/PHASE2active not recruiting

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

211 enrolled

NCT03467373PHASE1completed

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

111 enrolled

2017

NCT03274492PHASE3completed

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

1,000 enrolled

2016

NCT02729896PHASE1/PHASE2completed

A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

36 enrolled

NCT02600897PHASE1/PHASE2completed

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

114 enrolled

NCT02611323PHASE1/PHASE2completed

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

133 enrolled

2014

NCT02257567PHASE1/PHASE2completed

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

331 enrolled

2013

NCT01992653PHASE1/PHASE2completed

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

85 enrolled

2012

NCT01691898PHASE1/PHASE2completed

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

231 enrolled

2011

NCT01290549PHASE1completed

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

95 enrolled

Conditions Under Study

Condition	NCT ID	Title	Status	Phase	Enrollment
Diffuse Large B-Cell Lymphoma	NCT06665217	G-Pola-ZLP in Diffuse Large B-Cell Lymphoma	not yet recruiting	PHASE2	80
	NCT07012980	Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL	not yet recruiting	PHASE2	38
	NCT07001540	Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation	recruiting	PHASE2	130
	NCT06803693	Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL	recruiting	PHASE2	152
	NCT06441097	Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL	not yet recruiting	PHASE2	152
	NCT06664411	Pola-ZR2P in Previously Untreated DLBCL	recruiting	PHASE2	80
	NCT06522555	The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma	recruiting	PHASE3	100
	NCT05954910	A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma	active not recruiting	N/A	1,000
	NCT05633615	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	396
	NCT05498220	Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma	terminated	PHASE2	5
	NCT05455697	Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	recruiting	PHASE1/PHASE2	35
	NCT04739813	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma	active not recruiting	PHASE1	34
	NCT04479267	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma	active not recruiting	PHASE2	8
	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
	NCT04182204	A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	completed	PHASE3	270
	NCT03677154	Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma	completed	PHASE1/PHASE2	188
	NCT03274492	A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma	completed	PHASE3	1,000
	NCT01691898	A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)	completed	PHASE1/PHASE2	231
Diffuse Large B Cell Lymphoma	NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	not yet recruiting	PHASE2	30
	NCT06516978	A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL	not yet recruiting	PHASE2	528
	NCT06530511	Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL	recruiting	PHASE2	30
	NCT06176729	Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients	recruiting	PHASE2	30
	NCT05940051	Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma	unknown	PHASE2	35
	NCT05940064	Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma	unknown	PHASE2	30
	NCT04491370	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	20
	NCT04914741	A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)	active not recruiting	PHASE1/PHASE2	80
	NCT04535102	POLA+BR for Relapsed or Refractory DLBCL	withdrawn	PHASE2	0
Lymphoma	NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	not yet recruiting	PHASE2	30
	NCT05800366	A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma	recruiting	PHASE2	41
	NCT04739813	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma	active not recruiting	PHASE1	34
	NCT02729896	A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	completed	PHASE1/PHASE2	36
	NCT02257567	A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma	completed	PHASE1/PHASE2	331
Non-Hodgkin Lymphoma	NCT05283720	A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma	recruiting	PHASE2	496
	NCT05171647	A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma	active not recruiting	PHASE3	208
	NCT05169658	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	completed	PHASE2	42
	NCT04739813	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma	active not recruiting	PHASE1	34
	NCT03467373	A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL	completed	PHASE1	111
Lymphoma, B-Cell	NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	not yet recruiting	PHASE2	30
	NCT04882163	Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma	withdrawn	PHASE1/PHASE2	0
	NCT04594798	A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL	active not recruiting	PHASE2	39
	NCT04884035	Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma	recruiting	PHASE1	224
Lymphoma, Large B-Cell, Diffuse	NCT06890884	A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)	recruiting	PHASE2	594
	NCT05800366	A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma	recruiting	PHASE2	41
	NCT05798156	Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP	active not recruiting	PHASE2	125
	NCT04790903	A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)	terminated	PHASE1	50
Diffuse Large B-cell Lymphoma	NCT06665217	G-Pola-ZLP in Diffuse Large B-Cell Lymphoma	not yet recruiting	PHASE2	80
	NCT07012980	Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL	not yet recruiting	PHASE2	38
	NCT07001540	Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation	recruiting	PHASE2	130
	NCT06803693	Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL	recruiting	PHASE2	152
	NCT06441097	Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL	not yet recruiting	PHASE2	152
	NCT06664411	Pola-ZR2P in Previously Untreated DLBCL	recruiting	PHASE2	80
	NCT06522555	The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma	recruiting	PHASE3	100
	NCT05954910	A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma	active not recruiting	N/A	1,000
	NCT05633615	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	396
	NCT05498220	Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma	terminated	PHASE2	5
	NCT05455697	Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	recruiting	PHASE1/PHASE2	35
	NCT04739813	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma	active not recruiting	PHASE1	34
	NCT04479267	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma	active not recruiting	PHASE2	8
	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
	NCT04182204	A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	completed	PHASE3	270
	NCT03677154	Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma	completed	PHASE1/PHASE2	188
	NCT03274492	A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma	completed	PHASE3	1,000
	NCT01691898	A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)	completed	PHASE1/PHASE2	231
High-grade B-cell Lymphoma	NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	not yet recruiting	PHASE2	30
	NCT04914741	A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)	active not recruiting	PHASE1/PHASE2	80
	NCT04479267	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma	active not recruiting	PHASE2	8
Follicular Lymphoma	NCT05410418	Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma	active not recruiting	PHASE2	34
	NCT04491370	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	20
	NCT01691898	A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)	completed	PHASE1/PHASE2	231
Refractory Diffuse Large B-Cell Lymphoma	NCT05633615	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	396
	NCT04833114	Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)	completed	PHASE3	306
	NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	41
Chronic Lymphocytic Leukemia	NCT06043674	Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation	recruiting	PHASE2	70
	NCT04679012	Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation	recruiting	PHASE2	20
	NCT01290549	A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma	completed	PHASE1	95
B-Cell Lymphoma	NCT05615636	A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL	recruiting	PHASE2	36
	NCT04491370	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	20
	NCT03467373	A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL	completed	PHASE1	111
Aggressive Non-Hodgkin Lymphoma	NCT05260957	CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).	recruiting	PHASE2	22
	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
B-cell Non-Hodgkin Lymphoma	NCT04970901	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	recruiting	PHASE1	200
	NCT03677141	A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma	completed	PHASE1/PHASE2	117
	NCT03671018	A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma	active not recruiting	PHASE1/PHASE2	422
Burkitt Lymphoma	NCT04491370	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	20
	NCT04739813	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma	active not recruiting	PHASE1	34
Diffuse Large B-Cell Lymphoma (DLBCL)	NCT07397832	CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL	recruiting	PHASE2	58
	NCT04624893	A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin	unknown	N/A	35
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	NCT06015880	Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	recruiting	PHASE1	30
	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
Diffuse Large B Cell Lymphoma (DLBCL)	NCT06594939	Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma	not yet recruiting	PHASE2	31
	NCT06765317	A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma	recruiting	PHASE2	42
DLBCL - Diffuse Large B Cell Lymphoma	NCT07231250	Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma	not yet recruiting	PHASE2	40
	NCT07034508	A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1	not yet recruiting	PHASE2	134
Grade 3b Follicular Lymphoma	NCT05633615	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	396
	NCT05455697	Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	recruiting	PHASE1/PHASE2	35
High Grade B-Cell Lymphoma	NCT06015880	Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	recruiting	PHASE1	30
	NCT05455697	Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	recruiting	PHASE1/PHASE2	35
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
Hodgkin Lymphoma	NCT05615636	A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL	recruiting	PHASE2	36
	NCT04491370	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	20
Large B-Cell Lymphoma (LBCL)	NCT07594899	AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL	not yet recruiting	PHASE2	178
	NCT07514169	The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL	recruiting	PHASE2	30
Marginal Zone Lymphoma	NCT05169658	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	completed	PHASE2	42
	NCT04491370	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	20
Non-Hodgkins Lymphoma	NCT03533283	An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	active not recruiting	PHASE1/PHASE2	211
	NCT01290549	A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma	completed	PHASE1	95
Recurrent Diffuse Large B-Cell Lymphoma	NCT05633615	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	396
	NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	41
Recurrent Grade 1 Follicular Lymphoma	NCT06453044	Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma	recruiting	PHASE2	41
	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Recurrent Grade 2 Follicular Lymphoma	NCT06453044	Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma	recruiting	PHASE2	41
	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Recurrent Grade 3a Follicular Lymphoma	NCT06453044	Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma	recruiting	PHASE2	41
	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Refractory B-Cell Non-Hodgkin Lymphoma	NCT04970901	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	recruiting	PHASE1	200
	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Refractory Grade 1 Follicular Lymphoma	NCT06453044	Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma	recruiting	PHASE2	41
	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Refractory Grade 2 Follicular Lymphoma	NCT06453044	Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma	recruiting	PHASE2	41
	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Refractory Grade 3a Follicular Lymphoma	NCT06453044	Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma	recruiting	PHASE2	41
	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Richter Syndrome	NCT04679012	Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation	recruiting	PHASE2	20
	NCT04491370	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	20
Ann Arbor Stage III Marginal Zone Lymphoma	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
Grade 1 Follicular Lymphoma	NCT05169658	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	completed	PHASE2	42
Grade 2 Follicular Lymphoma	NCT05169658	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	completed	PHASE2	42
Grade 3a Follicular Lymphoma	NCT05169658	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	completed	PHASE2	42
Refractory Transformed B-Cell Non-Hodgkin Lymphoma	NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	41
Gray-Zone Lymphoma	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
Ann Arbor Stage III Follicular Lymphoma	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
Relapsed and Refractory DLBCL	NCT07122609	Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma	not yet recruiting	PHASE2	22
High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements	NCT04479267	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma	active not recruiting	PHASE2	8
High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements	NCT04479267	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma	active not recruiting	PHASE2	8
Relapsed B-cell NHL	NCT05615636	A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL	recruiting	PHASE2	36
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
High Grade B-Cell Lymphoma, Not Otherwise Specified	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
High Grade B Cell Lymphoma	NCT06765317	A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma	recruiting	PHASE2	42
Relapsed B-Cell Non-Hodgkin Lymphoma	NCT04970901	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	recruiting	PHASE1	200
Indolent B-Cell Non-Hodgkin Lymphoma	NCT05169658	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	completed	PHASE2	42
Indolent Non-Hodgkin Lymphoma	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
Large B-cell Lymphoma	NCT06071871	A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma	recruiting	PHASE2	99
	NCT06047080	An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma	active not recruiting	PHASE3	1,130
Large B-Cell Lymphoma	NCT06071871	A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma	recruiting	PHASE2	99
	NCT06047080	An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma	active not recruiting	PHASE3	1,130
Relapsed Diffuse Large B-cell Lymphoma	NCT04833114	Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)	completed	PHASE3	306
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
Ann Arbor Stage II Marginal Zone Lymphoma	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
Lymphoma, Follicular	NCT05410418	Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma	active not recruiting	PHASE2	34
Ann Arbor Stage II Follicular Lymphoma	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
Lymphoma, Mantle-Cell	NCT04913103	Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL	not yet recruiting	PHASE2	21
Lymphoma, Non Hodgkin	NCT01992653	A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma	completed	PHASE1/PHASE2	85
Mantle-cell Lymphoma	NCT05868395	Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma	recruiting	PHASE2	16
Mantle Cell Lymphoma	NCT04491370	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	20
Relapsed Non Hodgkin Lymphoma	NCT05260957	CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).	recruiting	PHASE2	22
Non-Hodgkin's Lymphoma	NCT02611323	A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)	completed	PHASE1/PHASE2	133
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
Relapsed or Refractory Diffuse Large B-Cell Lymphoma	NCT04607772	Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)	withdrawn	PHASE1/PHASE2	0
Post-transplant Lymphoproliferative Disorder	NCT06040320	Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)	recruiting	PHASE1/PHASE2	12
Primary Mediastinal (Thymic) Large B-Cell Lymphoma	NCT05633615	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	396
Primary Mediastinal Large B-Cell Lymphoma	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
Recurrent B-Cell Non-Hodgkin Lymphoma	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma	NCT02600897	A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	completed	PHASE1/PHASE2	114
Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue	NCT05169658	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	completed	PHASE2	42
Richter's Transformation	NCT06043674	Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation	recruiting	PHASE2	70
Transformed Non-Hodgkin Lymphoma	NCT04491370	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	20
Safety Issues	NCT06468943	Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL	enrolling by invitation	PHASE2	20
Recurrent Mantle Cell Lymphoma	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Recurrent Marginal Zone Lymphoma	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma	NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	41
Recurrent Small Lymphocytic Lymphoma	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma	NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	41
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
ALK-Positive Large B-Cell Lymphoma	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue	NCT05169658	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	completed	PHASE2	42
Transformed Follic Lymph to Diff Large B-Cell Lymphoma	NCT05633615	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	396
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma	NCT06015880	Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	recruiting	PHASE1	30
Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma	NCT05633615	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	396
Aggressive B-Cell Lymphoma	NCT07184788	G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma	not yet recruiting	PHASE2	80
Refractory Mantle Cell Lymphoma	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
B-Cell Non-Hodgkin Lymphoma	NCT04970901	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	recruiting	PHASE1	200
	NCT03677141	A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma	completed	PHASE1/PHASE2	117
	NCT03671018	A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma	active not recruiting	PHASE1/PHASE2	422
Bispecific Antibody	NCT07231250	Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma	not yet recruiting	PHASE2	40
Refractory Marginal Zone Lymphoma	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Chemo-free Therapy	NCT07231250	Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma	not yet recruiting	PHASE2	40
B-cell Lymphoma	NCT05615636	A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL	recruiting	PHASE2	36
	NCT04491370	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	20
	NCT03467373	A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL	completed	PHASE1	111
CNS Lymphoma	NCT06730542	Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma	recruiting	PHASE1	20
Ann Arbor Stage IV Marginal Zone Lymphoma	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
Ann Arbor Stage IV Follicular Lymphoma	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
Refractory Non-Hodgkin Lymphoma	NCT05260957	CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).	recruiting	PHASE2	22
Diffuse Large B-Cell Lymphoma Unclassifiable	NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	41
Refractory or Relapsed Diffuse Large B Cell Lymphoma	NCT06554600	A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	36
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma	NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	41
Diffuse, Large B-Cell, Lymphoma	NCT04236141	A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).	terminated	PHASE3	42
DLBCL	NCT04594798	A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL	active not recruiting	PHASE2	39
Refractory Small Lymphocytic Lymphoma	NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3
Double Expressor DLBCL	NCT07415980	Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL	not yet recruiting	PHASE1/PHASE2	68
Double Expressor Lymphoma	NCT04479267	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma	active not recruiting	PHASE2	8
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
Effects of Chemotherapy	NCT06468943	Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL	enrolling by invitation	PHASE2	20

All Polatuzumab Vedotin Clinical Trials (80)

NCT ID	Title	Status	Phase	Enrollment	Sponsor
NCT06594939	Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma	not yet recruiting	PHASE2	31	Medical College of Wisconsin
NCT07594899	AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL	not yet recruiting	PHASE2	178	Ruijin Hospital
NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	not yet recruiting	PHASE2	30	Brown University
NCT07415980	Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL	not yet recruiting	PHASE1/PHASE2	68	Sun Yat-sen University
NCT07514169	The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL	recruiting	PHASE2	30	Ruijin Hospital
NCT07397832	CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL	recruiting	PHASE2	58	Tianjin Medical University Cancer Institute and Hospital
NCT07231250	Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma	not yet recruiting	PHASE2	40	Li Zhiming
NCT07184788	G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma	not yet recruiting	PHASE2	80	Navy General Hospital, Beijing
NCT06665217	G-Pola-ZLP in Diffuse Large B-Cell Lymphoma	not yet recruiting	PHASE2	80	Navy General Hospital, Beijing
NCT07122609	Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma	not yet recruiting	PHASE2	22	Ruijin Hospital
NCT07034508	A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1	not yet recruiting	PHASE2	134	Institute of Hematology & Blood Diseases Hospital, China
NCT07012980	Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL	not yet recruiting	PHASE2	38	Shanghai Zhongshan Hospital
NCT07001540	Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation	recruiting	PHASE2	130	Fudan University
NCT06730542	Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma	recruiting	PHASE1	20	Juan P. Alderuccio, MD
NCT06890884	A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)	recruiting	PHASE2	594	Merck Sharp & Dohme LLC
NCT06803693	Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL	recruiting	PHASE2	152	Ruijin Hospital
NCT06765317	A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma	recruiting	PHASE2	42	Memorial Sloan Kettering Cancer Center
NCT06441097	Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL	not yet recruiting	PHASE2	152	Ruijin Hospital
NCT06516978	A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL	not yet recruiting	PHASE2	528	The First Affiliated Hospital with Nanjing Medical University
NCT06664411	Pola-ZR2P in Previously Untreated DLBCL	recruiting	PHASE2	80	Navy General Hospital, Beijing
NCT06453044	Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma	recruiting	PHASE2	41	City of Hope Medical Center
NCT06554600	A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	36	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06071871	A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma	recruiting	PHASE2	99	University College, London
NCT06530511	Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL	recruiting	PHASE2	30	Affiliated Hospital of Nantong University
NCT06522555	The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma	recruiting	PHASE3	100	Ruijin Hospital
NCT06015880	Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	recruiting	PHASE1	30	National Cancer Institute (NCI)
NCT06043674	Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation	recruiting	PHASE2	70	Christine Ryan
NCT05868395	Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma	recruiting	PHASE2	16	Medical University of Vienna
NCT06176729	Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients	recruiting	PHASE2	30	Yan Zhang, MD
NCT06040320	Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)	recruiting	PHASE1/PHASE2	12	Washington University School of Medicine
NCT06047080	An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma	active not recruiting	PHASE3	1,130	Hoffmann-La Roche
NCT05954910	A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma	active not recruiting	N/A	1,000	Hoffmann-La Roche
NCT05940051	Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma	unknown	PHASE2	35	Peng Liu
NCT05940064	Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma	unknown	PHASE2	30	Peng Liu
NCT06468943	Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL	enrolling by invitation	PHASE2	20	The First Affiliated Hospital of Soochow University
NCT05633615	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	396	SWOG Cancer Research Network
NCT05615636	A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL	recruiting	PHASE2	36	M.D. Anderson Cancer Center
NCT05800366	A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma	recruiting	PHASE2	41	Jennifer Crombie, MD
NCT05798156	Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP	active not recruiting	PHASE2	125	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT05498220	Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma	terminated	PHASE2	5	UNC Lineberger Comprehensive Cancer Center
NCT05455697	Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	recruiting	PHASE1/PHASE2	35	University of Washington
NCT05260957	CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).	recruiting	PHASE2	22	Lazaros Lekakis
NCT05410418	Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma	active not recruiting	PHASE2	34	Washington University School of Medicine
NCT04970901	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	recruiting	PHASE1	200	ADC Therapeutics S.A.
NCT05283720	A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma	recruiting	PHASE2	496	Genmab
NCT05171647	A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma	active not recruiting	PHASE3	208	Hoffmann-La Roche
NCT05169658	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	completed	PHASE2	42	University of Washington
NCT04882163	Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma	withdrawn	PHASE1/PHASE2	0	Celgene
NCT04679012	Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation	recruiting	PHASE2	20	Weill Medical College of Cornell University
NCT04594798	A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL	active not recruiting	PHASE2	39	University of Rochester
NCT04884035	Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma	recruiting	PHASE1	224	Celgene
NCT04913103	Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL	not yet recruiting	PHASE2	21	Czech Lymphoma Study Group
NCT04491370	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	20	New York Medical College
NCT04739813	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma	active not recruiting	PHASE1	34	National Cancer Institute (NCI)
NCT04790903	A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)	terminated	PHASE1	50	Hoffmann-La Roche
NCT04914741	A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)	active not recruiting	PHASE1/PHASE2	80	Peter MacCallum Cancer Centre, Australia
NCT04833114	Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)	completed	PHASE3	306	GWT-TUD GmbH
NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	terminated	PHASE2	3	Academic and Community Cancer Research United
NCT04535102	POLA+BR for Relapsed or Refractory DLBCL	withdrawn	PHASE2	0	University of Colorado, Denver
NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	41	City of Hope Medical Center
NCT04607772	Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)	withdrawn	PHASE1/PHASE2	0	Karyopharm Therapeutics Inc
NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56	University of Washington
NCT04479267	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma	active not recruiting	PHASE2	8	Barbara Ann Karmanos Cancer Institute
NCT04236141	A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).	terminated	PHASE3	42	Hoffmann-La Roche
NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	active not recruiting	PHASE1	50	Mayo Clinic
NCT04182204	A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	completed	PHASE3	270	Hoffmann-La Roche
NCT04624893	A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin	unknown	N/A	35	Jiangsu Cancer Institute & Hospital
NCT03677154	Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma	completed	PHASE1/PHASE2	188	Hoffmann-La Roche
NCT03677141	A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma	completed	PHASE1/PHASE2	117	Hoffmann-La Roche
NCT03671018	A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma	active not recruiting	PHASE1/PHASE2	422	Hoffmann-La Roche
NCT03533283	An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	active not recruiting	PHASE1/PHASE2	211	Hoffmann-La Roche
NCT03467373	A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL	completed	PHASE1	111	Hoffmann-La Roche
NCT03274492	A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma	completed	PHASE3	1,000	Hoffmann-La Roche
NCT02729896	A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	completed	PHASE1/PHASE2	36	Hoffmann-La Roche
NCT02600897	A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	completed	PHASE1/PHASE2	114	Hoffmann-La Roche
NCT02611323	A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)	completed	PHASE1/PHASE2	133	Hoffmann-La Roche
NCT02257567	A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma	completed	PHASE1/PHASE2	331	Hoffmann-La Roche
NCT01992653	A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma	completed	PHASE1/PHASE2	85	Genentech, Inc.
NCT01691898	A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)	completed	PHASE1/PHASE2	231	Genentech, Inc.
NCT01290549	A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma	completed	PHASE1	95	Genentech, Inc.

Where to Participate: All Polatuzumab Vedotin Trial Sites in the U.S. (231 sites across 42 states)

Every actively recruiting Polatuzumab Vedotintrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	University Hospital (University Of Alabama Hospital)	Birmingham35233	NCT04884035	Map
AL	Infirmary Cancer Care ( Site 0157)	Mobile36607	NCT06890884	Map
AZ	Ironwood Cancer & Research Centers ( Site 0204)	Chandler85224	NCT06890884	Map
AZ	Palo Verde Cancer Specialists ( Site 0105)	Glendale85304	NCT06890884	Map
AZ	City of Hope - Phoenix ( Site 0202)	Goodyear85338	NCT06890884	Map
AZ	Mayo Clinic - Arizona	Scottsdale85259	NCT04884035	Map
AZ	Banner University Medical Center - Tucson	Tucson85719	NCT05633615	Map
AZ	University of Arizona Cancer Center-North Campus	Tucson85719	NCT05633615	Map
AR	Highlands Oncology Group - Fayetteville	Fayetteville72703	NCT05633615	Map
AR	Genesis Cancer and Blood Institute ( Site 0193)	Hot Springs71913	NCT06890884	Map
AR	University of Arkansas for Medical Sciences	Little Rock72205	NCT05633615	Map
AR	Highlands Oncology Group - Rogers	Rogers72758	NCT05633615	Map
AR	Highlands Oncology Group	Springdale72762	NCT05633615	Map
CA	Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135)	Burbank91505	NCT06890884	Map
CA	University of California San Francisco - Fresno Center for Medical Education and Research	Clovis93611	NCT04970901	Map
CA	UC Irvine Health Cancer Center-Newport	Costa Mesa92627	NCT05633615	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06015880	Map
CA	City of Hope Comprehensive Cancer Center ( Site 0191)	Duarte91010	NCT06890884	Map
CA	City of Hope Medical Center	Duarte91010	NCT06453044	Map
CA	City Of Hope National Medical Center	Duarte91010	NCT04884035	Map
CA	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	Irvine92612	NCT05633615	Map
CA	UCI Health Laguna Hills	Laguna Hills92653	NCT05633615	Map
CA	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange92868	NCT05633615	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT06015880	Map
CA	Scripps Health - Prebys Cancer Center	San Diego92103	NCT04970901	Map
CA	UCSF Medical Center-Parnassus	San Francisco94143	NCT05633615	Map
CA	Bass Medical Group ( Site 0123)	Walnut Creek94598	NCT06890884	Map
CO	Rocky Mountain Cancer Centers (RMCC) ( Site 8001)	Aurora80012	NCT06890884	Map
CO	Colorado West Healthcare System-Grand Valley Oncology ( Site 0165)	Grand Junction81505	NCT06890884	Map
CT	Yale University School of Medicine /ID# 242089	New Haven06510	NCT05283720	Map
DE	Christiana Care Health Service /ID# 242301	Newark19713	NCT05283720	Map
DE	Medical Oncology Hematology Consultants (MOHC) ( Site 8007)	Newark19713	NCT06890884	Map
DC	Georgetown University Medical Center ( Site 0117)	Washington D.C.20007	NCT06890884	Map
FL	Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130)	Boca Raton33486	NCT06890884	Map
FL	UF Health Cancer Institute - Gainesville	Gainesville32610	NCT05633615	Map
FL	Baptist MD Anderson Cancer Center ( Site 0176)	Jacksonville32207	NCT06890884	Map
FL	Mayo Clinic Jacksonville - PPDS	Jacksonville32224	NCT04884035	Map
FL	Miami Cancer Institute	Miami33176	NCT04970901	Map
FL	Sylvester Comprehensive Cancer Center	Miami33136	NCT04970901	Map
FL	University of Miami	Miami33136	NCT05260957	Map
FL	University of Miami	Miami33136	NCT06730542	Map
FL	University of Miami Sylvester Cancer Center	Miami33136	NCT05800366	Map
FL	Mount Sinai Braman Comprehensive Cancer Center ( Site 0140)	Miami Beach33140	NCT06890884	Map
FL	Mid Florida Hematology and Oncology Center ( Site 0152)	Orange City32763	NCT06890884	Map
FL	Memorial Cancer Institute - Memorial Hospital West	Pembroke Pines33028	NCT04970901	Map
FL	Tampa General Hospital /ID# 246748	Tampa33606	NCT05283720	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT05633615	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT05633615	Map
GA	The Blood and Marrow Transplant Group of Georgia	Atlanta30342	NCT04970901	Map
GA	Winship Cancer Institute at Emory University	Atlanta30322	NCT06043674	Map
GA	Winship Cancer Institute of Emory University	Atlanta30322	NCT04970901	Map
GA	Northwest Georgia Oncology Centers PC	Marietta30060	NCT04884035	Map
ID	Saint Luke's Cancer Institute - Boise	Boise83712	NCT05633615	Map
ID	Saint Luke's Cancer Institute - Fruitland	Fruitland83619	NCT05633615	Map
ID	Saint Luke's Cancer Institute - Meridian	Meridian83642	NCT05633615	Map
ID	Saint Luke's Cancer Institute - Nampa	Nampa83687	NCT05633615	Map
ID	Beacon Cancer Care ( Site 0142)	Post Falls83854	NCT06890884	Map
ID	Saint Luke's Cancer Institute - Twin Falls	Twin Falls83301	NCT05633615	Map
IL	Northwestern University	Chicago60611	NCT06015880	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT05633615	Map
IL	University of Chicago Medical Center ( Site 0126)	Chicago60637	NCT06890884	Map
IL	University of Illinois	Chicago60612	NCT05633615	Map
IL	Illinois Cancer Care ( Site 7005)	Peoria61615	NCT06890884	Map
IA	Mission Cancer + Blood - Mission Cancer Foundation	Des Moines50309	NCT04970901	Map
IA	University of Iowa-Holden Comprehensive Cancer Center ( Site 0139)	Iowa City52242	NCT06890884	Map
IA	University of Iowa/Holden Comprehensive Cancer Center	Iowa City52242	NCT05633615	Map
IA	Mission Blood & Cancer Care ( Site 0114)	Waukee50263	NCT06890884	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT05633615	Map
KS	University Of Kansas Medical Center	Kansas City66160	NCT04884035	Map
KS	University of Kansas Cancer Center-Overland Park	Overland Park66210	NCT05633615	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT05633615	Map
KS	Cancer Center Of Kansas-Wichita	Wichita67214	NCT04884035	Map
KY	Saint Elizabeth Medical Center Edgewood ( Site 0141)	Edgewood41017	NCT06890884	Map
KY	Baptist Health Hardin ( Site 0154)	Elizabethtown42701	NCT06890884	Map
KY	Baptist Health Lexington ( Site 0127)	Lexington40503	NCT06890884	Map
KY	Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0185)	Louisville40207	NCT06890884	Map
KY	The James Graham Brown Cancer Center at University of Louisville	Louisville40202	NCT05633615	Map
KY	UofL Health Medical Center Northeast	Louisville40245	NCT05633615	Map
LA	Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180)	Baton Rouge70808	NCT06890884	Map
LA	Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209)	Monroe71202	NCT06890884	Map
LA	Ochsner Clinic Foundation ( Site 0189)	New Orleans70121	NCT06890884	Map
LA	Louisiana State University Health Sciences Shreveport ( Site 0195)	Shreveport71103	NCT06890884	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT05633615	Map
MD	University of Maryland, Baltimore /ID# 242218	Baltimore21201	NCT05283720	Map
MD	University of Maryland/Greenebaum Cancer Center	Baltimore21201	NCT05633615	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT04970901	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT05800366	Map
MA	Brigham and Women's Hospital	Boston02215	NCT06043674	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT05800366	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06043674	Map
MA	Dana Farber Cancer Institute ( Site 0111)	Boston02215	NCT06890884	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT04970901	Map
MI	Bronson Battle Creek	Battle Creek49017	NCT05633615	Map
MI	Henry Ford Hospital	Detroit48202	NCT05633615	Map
MI	Wayne State University/Karmanos Cancer Institute	Detroit48201	NCT05633615	Map
MI	Weisberg Cancer Treatment Center	Farmington Hills48334	NCT05633615	Map
MI	Corewell Health Grand Rapids Hospitals - Butterworth Hospital	Grand Rapids49503	NCT05633615	Map
MI	Trinity Health Grand Rapids Hospital	Grand Rapids49503	NCT05633615	Map
MI	Beacon Kalamazoo Cancer Center	Kalamazoo49009	NCT05633615	Map
MI	Bronson Methodist Hospital	Kalamazoo49007	NCT05633615	Map
MI	West Michigan Cancer Center	Kalamazoo49007	NCT05633615	Map
MI	Trinity Health Muskegon Hospital	Muskegon49444	NCT05633615	Map
MI	Corewell Health Lakeland Hospitals - Niles Hospital	Niles49120	NCT05633615	Map
MI	Cancer and Hematology Centers of Western Michigan - Norton Shores	Norton Shores49444	NCT05633615	Map
MI	Corewell Health Reed City Hospital	Reed City49677	NCT05633615	Map
MI	Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center	Saint Joseph49085	NCT05633615	Map
MI	Munson Medical Center	Traverse City49684	NCT05633615	Map
MI	University of Michigan Health - West	Wyoming49519	NCT05633615	Map
MN	Minnesota Oncology Hematology (MNO) ( Site 8004)	Burnsville55337	NCT06890884	Map
MN	University of Minnesota	Minneapolis55455	NCT04970901	Map
MN	Mayo Clinic - Rochester	Rochester55905-0001	NCT04884035	Map
MN	HealthPartners Cancer Research Center	Saint Louis Park55426	NCT04884035	Map
MO	Washington University School of Medicine	St Louis63110	NCT06040320	Map
MT	Bozeman Health Deaconess Hospital ( Site 0183)	Bozeman59715	NCT06890884	Map
NE	NHO Revive Research Institute, LLC ( Site 0121)	Lincoln68506	NCT06890884	Map
NE	University of Nebraska - Fred and Pamela Buffet Center	Omaha68198	NCT04884035	Map
NE	University Of Nebraska Medical Center ( Site 0110)	Omaha68198	NCT06890884	Map
NH	Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center	Lebanon03756	NCT05633615	Map
NJ	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT06765317	Map
NJ	Hackensack Meridian Health (Data collection only)	Hackensack07601	NCT06765317	Map
NJ	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown07748	NCT06765317	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT06765317	Map
NJ	Atlantic Health Morristown Medical Center ( Site 0163)	Morristown07960	NCT06890884	Map
NJ	Valley Health Systems - Ridgewood Campus ( Site 0125)	Paramus07652	NCT06890884	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT05633615	Map
NY	Erie County Medical Center ( Site 0175)	Buffalo14215	NCT06890884	Map
NY	Roswell Park Cancer Institute ( Site 0192)	Buffalo14263	NCT06890884	Map
NY	Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)	Commack11725	NCT06765317	Map
NY	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison10604	NCT06765317	Map
NY	Northwell Health - Monter Cancer Center /ID# 245435	Lake Success11042	NCT05283720	Map
NY	Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0208)	Mineola11501	NCT06890884	Map
NY	Columbia University Irving Medical Center	New York10027	NCT04970901	Map
NY	Columbia University Medical Center	New York10032	NCT04679012	Map
NY	Icahn School of Medicine at Mount Sinai /ID# 242123	New York10029	NCT05283720	Map
NY	Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108)	New York10016	NCT06890884	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT06765317	Map
NY	Mount Sinai- Icahn School of Medicine	New York10029	NCT04679012	Map
NY	NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center	New York10032	NCT05633615	Map
NY	Weill Cornell Medicine	New York10065	NCT04679012	Map
NY	University of Rochester	Rochester14642	NCT05633615	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Rockville Centre11553	NCT06765317	Map
NY	SUNY Upstate Cancer Center ( Site 0178)	Syracuse13210	NCT06890884	Map
NY	New York Medical Center	Valhalla10595	NCT04491370	Map
NY	Wilmot Cancer Institute at Webster	Webster14580	NCT05633615	Map
NY	Clinical Research Alliance ( Site 0122)	Westbury11590	NCT06890884	Map
NC	The University of North Carolina at Chapel Hill	Chapel Hill27599	NCT06043674	Map
NC	University of North Carolina Medical Center ( Site 0136)	Chapel Hill27514	NCT06890884	Map
NC	Carolinas Medical Center/Levine Cancer Institute	Charlotte28203	NCT05633615	Map
NC	Levine Cancer Institute	Charlotte28204	NCT04884035	Map
NC	Novant Health Presbyterian Medical Center ( Site 0177)	Charlotte28204	NCT06890884	Map
NC	Atrium Health Cabarrus/LCI-Concord	Concord28025	NCT05633615	Map
NC	East Carolina University - Brody School of Medicine /ID# 242506	Greenville27834	NCT05283720	Map
NC	Atrium Health Wake Forest Baptist	Winston-Salem27157	NCT04884035	Map
NC	Novant Health Forsyth Medical Center ( Site 0206)	Winston-Salem27103	NCT06890884	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT05633615	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT06015880	Map
ND	Sanford Broadway Medical Center	Fargo58122	NCT05633615	Map
ND	Sanford Roger Maris Cancer Center	Fargo58122	NCT05633615	Map
OH	University of Cincinnati Medical Center ( Site 0156)	Cincinnati45219	NCT06890884	Map
OH	Case Western Reserve University	Cleveland44106	NCT05633615	Map
OH	Case Western Reserve University	Cleveland44106	NCT06015880	Map
OH	Cleveland Clinic Main ( Site 0101)	Cleveland44195	NCT06890884	Map
OH	Cleveland Clinic Main Campus	Cleveland44195	NCT04970901	Map
OH	Fairview Hospital-Moll Cancer Center ( Site 0198)	Cleveland44111	NCT06890884	Map
OH	University Hospitals of Cleveland ( Site 0155)	Cleveland44106	NCT06890884	Map
OH	Ohio state University	Columbus43210	NCT04679012	Map
OH	The Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06043674	Map
OH	Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 0199)	Mayfield Heights44124	NCT06890884	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT05633615	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06015880	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT05633615	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT05633615	Map
OR	Oregon Health and Science University	Portland97239	NCT04970901	Map
OR	Oregon Health and Science University	Portland97239	NCT05633615	Map
OR	Providence Oncology and Hematology Clinic Westside ( Site 0179)	Portland97225	NCT06890884	Map
OR	Providence Portland Medical Center	Portland97213	NCT05633615	Map
OR	Providence Portland Medical Center ( Site 0120)	Portland97213	NCT06890884	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT05633615	Map
PA	Geisinger Medical Center	Danville17822	NCT05633615	Map
PA	Penn Medicine - Perelman Center for Advanced Medicine	Philadelphia19104	NCT04970901	Map
PA	Temple University Hospital ( Site 0133)	Philadelphia19140	NCT06890884	Map
PA	University of Pennsylvania/Abramson Cancer Center	Philadelphia19104	NCT05633615	Map
PA	Alliance Cancer Specialists (ACS) ( Site 8010)	Sellersville18960	NCT06890884	Map
PA	Geisinger Wyoming Valley/Henry Cancer Center	Wilkes-Barre18711	NCT05633615	Map
PA	Cancer Care Associates Of York ( Site 0174)	York17403	NCT06890884	Map
RI	Brown University Health - Rhode Island Hospital	Providence02903	NCT04970901	Map
SC	Prisma Health Cancer Institute - Spartanburg	Boiling Springs29316	NCT05633615	Map
SC	Medical University of South Carolina	Charleston29425	NCT05633615	Map
SC	Medical University of South Carolina ( Site 0153)	Charleston29425	NCT06890884	Map
SC	Prisma Health Cancer Institute - Easley	Easley29640	NCT05633615	Map
SC	Prisma Health Cancer Institute - Butternut	Greenville29605	NCT05633615	Map
SC	Prisma Health Cancer Institute - Eastside	Greenville29615	NCT05633615	Map
SC	Prisma Health Cancer Institute - Faris	Greenville29605	NCT05633615	Map
SC	Prisma Health Cancer Institute - Greer	Greer29650	NCT05633615	Map
SC	Prisma Health Cancer Institute - Seneca	Seneca29672	NCT05633615	Map
TN	Tennessee Cancer Specialists ( Site 7004)	Knoxville37909	NCT06890884	Map
TN	Baptist Memorial Hospital and Cancer Center-Memphis	Memphis38120	NCT05633615	Map
TN	Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR)	Nashville37203	NCT04970901	Map
TN	SCRI Oncology Partners ( Site 7002)	Nashville37203	NCT06890884	Map
TX	Texas Oncology - West Texas ( Site 8008)	Amarillo79124	NCT06890884	Map
TX	Texas Oncology - Central/South Texas ( Site 8006)	Austin78705	NCT06890884	Map
TX	Baylor University Medical Center	Dallas75246	NCT04970901	Map
TX	M D Anderson Cancer Center	Houston77030	NCT05615636	Map
TX	MD Anderson Cancer Center	Houston77003	NCT04884035	Map
TX	Texas Oncology - Northeast Texas ( Site 8002)	Palestine75801	NCT06890884	Map
TX	Texas Oncology - San Antonio ( Site 8009)	San Antonio78240	NCT06890884	Map
UT	Intermountain Medical Center ( Site 0182)	Murray84107	NCT06890884	Map
UT	Intermountain Medical Oncology	Murray84107	NCT04884035	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT04970901	Map
UT	Intermountain Cancer Center - St George	St. George84790	NCT04884035	Map
UT	Intermountain Healthcare - St. George ( Site 0203)	St. George84790	NCT06890884	Map
VT	University of Vermont and State Agricultural College	Burlington05405	NCT05633615	Map
VT	University of Vermont Medical Center	Burlington05401	NCT05633615	Map
VT	Dartmouth Cancer Center - North	Saint Johnsbury05819	NCT05633615	Map
VA	Emily Couric Clinical Cancer Center	Charlottesville22903	NCT04970901	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT06015880	Map
VA	Virginia Cancer Specialists, PC ( Site 8003)	Manassas20110	NCT06890884	Map
VA	VCU Health Adult Outpatient Pavillion ( Site 0138)	Richmond23219	NCT06890884	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT05633615	Map
WA	Fred Hutch/University of Washington Cancer Consortium	Seattle98109	NCT05455697	Map
WA	Fred Hutch/University of Washington Cancer Consortium	Seattle98109	NCT04231877	Map
WA	Swedish Medical Center - Seattle /ID# 242269	Seattle98104	NCT05283720	Map
WA	Swedish Medical Center-First Hill	Seattle98122	NCT05633615	Map
WA	Northwest Cancer Specialists (Compass Oncology) ( Site 8000)	Vancouver98684	NCT06890884	Map
WI	SSM Health Dean Medical Group ( Site 0106)	Madison53715	NCT06890884	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT05633615	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT05633615	Map
WI	Froedtert & Medical College of Wisconsin	Milwaukee53226	NCT04970901	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT05633615	Map
WI	Medical College of Wisconsin ( Site 0103)	Milwaukee53226	NCT06890884	Map
WI	Froedtert and MCW Moorland Reserve Health Center	New Berlin53151	NCT05633615	Map

Browse Polatuzumab Vedotin Trials by State

New York clinical trials Massachusetts clinical trials Oregon clinical trials Georgia clinical trials Ohio clinical trials Pennsylvania clinical trials Florida clinical trials North Carolina clinical trials Illinois clinical trials California clinical trials

polatuzumab vedotindiffuse large b-cell lymphomadiffuse large b cell lymphomalymphomanon-hodgkin lymphomalymphoma, b-cellclinical trials

Data sourced from the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI). Report generated June 2, 2026.

What Is Polatuzumab Vedotin?

Uses and Conditions Under Study

Dosing

Side Effects

Clinical Trial Results

Currently Recruiting Trials

Where to Participate

Development Timeline

Polatuzumab Vedotin Development Timeline

Conditions Under Study

All Polatuzumab Vedotin Clinical Trials (80)

Sponsors

Where to Participate: All Polatuzumab Vedotin Trial Sites in the U.S. (231 sites across 42 states)

Browse Polatuzumab Vedotin Trials by State